Perrigo Co Plc

Health Care
Biotechnology: Pharmaceutical Preparations
www.perrigo.com

Earnings Score
Moat Score
Safety Score

Market Cap $3.83B
PE -24
Debt $4.75B
Cash $1.46B
EV $7.12B
FCF $151.70M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$159.60M
EBIT	-$16.90M
ROE	-3%
ROA	-0%
FCF	$151.70M
Equity	$4.57B
Growth Stability	-181%
PE	-24.01
PB	0.84
P/FCF	25.26
P/S	0.87
Price/Cash	0.38
Debt/Equity	1.04
Debt/FCF	31.33
Net Margins	-4%
Gross Margins	36%
Op. Margins	-0%
Earnings CAGR	0%
Sales Growth YoY	-3%
Sales Growth QoQ	2%
Sales CAGR	2%
FCF CAGR	-9%
Equity CAGR	-7%
Earnings Stability	0
Earnings Growth YoY	-247%
Earnings Growth QoQ	-81%
Sales CAGR 5Y	41%

FCF CAGR 5Y	-2%
Equity CAGR 5Y	-6%
Earnings CAGR 3Y	3%
Sales CAGR 3Y	3%
FCF CAGR 3Y	117%
Equity CAGR 3Y	-3%
Market Cap	$3.83B
Revenue	$4.39B
Dividend Yield	4%
Payout Ratio	-94%
Assets	$11.20B
Total Debt	$4.75B
Cash	$1.46B
Shares Outstanding	136.5M
EV	7.12B
Earnings Score	6%
Moat Score	12%
Safety Score	40%
Final Score	19%
Working Capital	2.26B
Current Ratio	2.56
Gross Profit	$1.58B
Shares Growth 3y	1%
Equity Growth QoQ	0%
Equity Growth YoY	-4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company's product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestitures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma.

SEC Filings

Direct access to Perrigo Co Plc (PRGO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 28
- 10-Q Jun 29
- 10-Q Mar 30
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jul 01
- 10-Q Apr 01
2022
- 10-K Dec 31
- 10-Q Oct 01
- 10-Q Jul 02
- 10-Q Apr 02

Sector Comparison

How does Perrigo Co Plc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Perrigo Co Plc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%

Stability 0%

loading chart...

Perrigo Co Plc Discounted Cash Flow

Fully customizable DCF calculator online for Perrigo Co Plc.

Years

Calculation mode

= $869M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$152M	$139M	$127M	$116M	$106M	$97M	$89M	$81M	$74M	$68M	$62M	$621M
DCF		$126M	$105M	$87M	$72M	$60M	$50M	$42M	$35M	$29M	$24M	$239M
Value	$869M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-76%	2%	3%	3%	-3%	-2%	-3%	-0%	-4%
ROA	-14%	5%	2%	2%	1%	4%	1%	1%	-0%
ROE	-67%	2%	2%	3%	-3%	-1%	-3%	-0%	-3%

Bad Net Margins (-3.93%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	10.57	5.47	6.61	14.11	7.66	838.21	19.47	13.41	31.33
Debt over Equity	0.97	0.54	0.57	0.58	0.63	0.68	0.85	0.85	1.04
Growth Stability	-	-	-	-	-123%	-181%	-	-	-181%

Bad Debt/FCF ratio (31.33)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Neutral Debt/Equity ratio (1.04)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-181%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-6%	-4%	2%	5%	-18%	8%	5%	41%
Earnings YoY growth	-	-103%	10%	12%	-211%	-58%	104%	-91%	-
Equity YoY growth	-	4%	-8%	2%	-3%	-9%	-6%	-2%	-6%
FCF YoY growth	-	11%	-20%	-51%	95%	-99%	5K%	44%	-2%